Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30459931 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL7102411 | 0.81 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL188578 | 0.79 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL26923027 | 0.79 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL31168037 | 0.78 | SOD1 (0.39) | — | |
| SCHEMBL30702019 | 0.78 | BACE1 (0.39) | — | |
| SCHEMBL27191843 | 0.78 | BACE1 (0.39) | — | |
| SCHEMBL27978363 | 0.78 | CYP1A1 (0.41) | — | |
| SCHEMBL27978105 | 0.78 | CYP11B1 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL15034034 | 0.78 | CHRNB1 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457346-A | Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3309152-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3309152-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2516417-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-9676759-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
| CN-102762548-B | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMA | 2014-11-26 | — | — | CN | disclosed |
| US-20140038936-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-06 | — | — | US | disclosed |
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2401273-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2398810-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011087776-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010135014-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010096389-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038936-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885 |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885 |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CG | CHRNB2 4045/4885CHRNA4 3874/4885 |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885 |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | CHRNB2 4059/4885CHRNA4 3915/4885 |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885 |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.